# A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu

Source: https://onco.cc/trials/nct03394365/  
OnCo record `nct03394365` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tabelecleucel run by Pierre Fabre Medicament, now recruiting.

## Summary

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy is a phase 3 interventional study registered as NCT03394365 by Pierre Fabre Medicament, with 115 participants planned, started 2017-12-29. Conditions listed: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03394365
- Phase: 3
- Setting: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy
- Sponsor: Pierre Fabre Medicament
- Enrolled: 115

## Sources

- ClinicalTrials.gov NCT03394365: https://clinicaltrials.gov/study/NCT03394365

## Connected records

- drugs: [Tabelecleucel](https://onco.cc/drugs/tabelecleucel/)

---
JSON: https://onco.cc/api/v1/entities/nct03394365.json